1 |
Deng, C., Pan, B. and O'Connor, O. A. (2013) Brentuximab vedotin. Clin. Cancer Res. 19, 22-27.
DOI
ScienceOn
|
2 |
Jain, N., Wierda, W., Ferrajoli, A., Wong, F., Lerner, S., Keating, M. and O'Brien, S. (2009) A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 115, 4533-4539.
DOI
ScienceOn
|
3 |
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J. H., Sliwkowski, M. X., Jacobson, F., Lutzker, S. G. and Burris, H. A. (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28, 2698-2704.
DOI
ScienceOn
|
4 |
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blattler, W. A., Lambert, J. M., Chari, R. V., Lutz, R. J., Wong, W. L., Jacobson, F. S., Koeppen, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D. and Sliwkowski, M. X. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290.
DOI
ScienceOn
|
5 |
Wakankar, A. A., Feeney, M. B., Rivera, J., Chen, Y., Kim, M., Sharma, V. K. and Wang, Y. J. (2010) Physicochemical stability of the antibody-drug conjugate Trastuzumab- DM1: changes due to modification and conjugation processes. Bioconjug. Chem. 21, 1588-1595.
DOI
ScienceOn
|
6 |
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., Lu, Y., Meng, Y. G., Ng, C., Yang, J., Lee, C. C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S. D., Lee Wong, W., Lowman, H. B., Vandlen, R., Sliwkowski, M. X., Scheller, R. H., Polakis, P. and Mallet, W. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925-932.
DOI
ScienceOn
|
7 |
Dirksen, A., Hackeng, T. M. and Dawson, P. E. (2006) Nucleophilic catalysis of oxime ligation. Angew. Chem. Int. Edit. 45, 7581-7584.
DOI
ScienceOn
|
8 |
Li, X., Yang, J. and Rader, C. (2013) Antibody conjugation via one and two C-terminal selenocysteines. Methods 65, 133-138.
|
9 |
Popkov, M., Gonzalez, B., Sinha, S. C. and Barbas, C. F. (2009) Instant immunity through chemically programmable vaccination and covalent self-assembly. P. Natl. Acad. Sci. U. S. A. 106, 4378-4383.
DOI
ScienceOn
|
10 |
Ghesani, M., Belgraier, A. and Hasni, S. (2003) Carcinoembryonic antigen (CEA) scan in the diagnosis of recurrent colorectal carcinoma in a patient with increasing CEA levels and inconclusive computed tomographic findings. Clin. Nucl. Med. 28, 608-609.
DOI
ScienceOn
|
11 |
Capizzi, R. L. (2004) Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas. Trans. Am. Clin. Climatol. Assoc. 115, 255-272.
|
12 |
Jakubowski, H. (2002) Understanding biochemical dissociation constants: A temporal perspective. J. Chem. Educ. 79, 968-971.
DOI
ScienceOn
|
13 |
Goldenberg, D. M., Rossi, E. A., Sharkey, R. M., McBride, W. J. and Chang, C. H. (2008) Multifunctional antibodies by the dock-and-lock method for improved cancer Imaging and therapy by pretargeting. J. Nucl. Med. 49, 158-163.
|
14 |
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J. H., Sliwkowski, M. X., Jacobson, F., Lutzker, S. G. and Burris, H. A. (2010) Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer. J. Clin. Oncol. 28, 2698-2704.
DOI
ScienceOn
|
15 |
Kontermann, R. E. (2012) Dual targeting strategies with bispecific antibodies. mAbs. 4, 182-197.
DOI
ScienceOn
|
16 |
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., McBride, W. J., Sharkey, R. M. and Chang, C. H. (2006) Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. P. Natl. Acad. Sci. U. S. A. 103, 6841-6846.
DOI
ScienceOn
|
17 |
Chang, C. H., Rossi, E. A. and Goldenberg, D. M. (2007) The dock and lock method: A novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin. Cancer Res. 13, 5586s-5591s.
DOI
ScienceOn
|
18 |
Kim, I. and Huestis, M. A. (2006) A validated method for the determination of nicotine, cotinine, trans-3'-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J. Mass Spectrom. 41, 815-821.
DOI
ScienceOn
|
19 |
Kosmas, C., Maraveyas, A., Gooden, C. S., Snook, D. and Epenetos, A. A. (1995) Anti-Chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal-antibody immunoconjugates for ovarian-cancer therapy. J. Nucl. Med. 36, 746-753.
|
20 |
Riah, O., Dousset, J. C., Courriere, P., Stigliani, J. L., Baziard-Mouysset, G. and Belahsen, Y. (1999) Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity. Toxicol. Lett. 109, 21-29.
DOI
ScienceOn
|
21 |
Moran, V. E. (2012) Cotinine : Beyond the expected, more than a biomarker of tobacco consumption. Front. Pharmacol. 3, 1-9.
|
22 |
Watanabe, N., Goodwin, D. A., Meares, C. F., Mctigue, M., Chaovapong, W., Ransone, C. M. and Renn, O. (1994) Immunogenicity in Rabbits and Mice of an Antibody-Chelate Conjugate - Comparison of (S) and (R) Macrocyclic Enantiomers and an Acyclic Chelating Agent. Cancer Res. 54, 1049-1054.
|
23 |
Kosmas, C., Snook, D., Gooden, C. S., Courtenayluck, N. S., Mccall, M. J., Meares, C. F. and Epenetos, A. A. (1992) Development of humoral immune-responses against a macrocyclic chelating agent (Dota) in cancer-patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res. 52, 904-911.
|
24 |
Baxter, A. B., Melnikoff, S., Stites, D. P. and Brasch, R. C. (1991) Immunogenicity of gadolinium-based contrast agents for magnetic-resonance-imaging - induction and characterization of antibodies in animals. Invest. Radiol. 26, 1035-1040.
|
25 |
Park, S., Lee, D. H., Park, J. G., Lee, Y. T. and Chung, J. (2010) A sensitive enzyme immunoassay for measuring cotinine in passive smokers. Clin. Chim. Acta. 411, 1238-1242.
DOI
ScienceOn
|
26 |
Park, S. (2012) Development of anti-cotinine antibody and its application to EIA and carrier for cotinine-conjugated molecule. Ph.D thesis, Seoul National University.
|
27 |
Wuellner, U., Gavrilyuk, J. I. and Barbas, C. F. (2010) Expanding the Concept of Chemically Programmable Antibodies to RNA Aptamers: Chemically Programmed Biotherapeutics. Angew. Chem. Int. Edit. 49, 5934-5937.
DOI
ScienceOn
|
28 |
Yoon, S., Kim, Y.-H., Kang, S. H., Kim, S.-K., Lee, H. K., Kim, H., Chung, J. and Kim, I.-H. (2013) Bispecific Her2 cotinine antibody in combination with cotinine-(histidine) 2-iodine for the pre-targeting of Her2-positive breast cancer xenografts. J. Cancer Res. Clin. 140, 227-233.
|
29 |
Kim, H., Park, S., Lee, H. K. and Chung, J. (2013) Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification. Exp. Mol. Med. 45, e43.
DOI
|
30 |
Apte, R. S. (2008) Pegaptanib sodium for the treatment of age-related macular degeneration. Expert. Opin. Pharmaco. 9, 499-508.
DOI
ScienceOn
|
31 |
Park, S., Hwang, D. and Chung, J. (2012) Cotinine-conjugated aptamer/anti-cotinine antibody complexes as a novel affinity unit for use in biological assays. Exp. Mol. Med. 44, 554-561.
DOI
ScienceOn
|
32 |
Sharkey, R. M., Chang, C. H., Rossi, E. A., McBride, W. J. and Goldenberg, D. M. (2012) Pretargeting: taking an alternate route for localizing radionuclides. Tumor Biol. 33, 591-600.
DOI
ScienceOn
|
33 |
Sharkey, R. M., Rossi, E. A., McBride, W. J., Chang, C. H. and Goldenberg, D. M. (2010) Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin. Nucl. Med. 40, 190-203.
DOI
ScienceOn
|
34 |
Sharkey, R. M., Karacay, H., Chang, C. H., McBride, W. J., Horak, I. D. and Goldenberg, D. M. (2005) Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 19, 1064-1069.
DOI
ScienceOn
|
35 |
Karacay, H., Brard, P. Y., Sharkey, R. M., Chang, C. H., Rossi, E. A., McBride, W., Ragland, D. R., Horak, I. D. and Goldenberg, D. M. (2005) Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin. Cancer Res. 11, 7879-7885.
DOI
ScienceOn
|
36 |
Rabuka, D., Rush, J. S., deHart, G. W., Wu, P. and Bertozzi, C. R. (2012) Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc. 7, 1052-1067.
DOI
ScienceOn
|
37 |
Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., Stafin, K., Lu, Y. C., Tran, H., Seller, A. J., Biroce, S. L., Szydlik, A., Pinkstaff, J. K., Tian, F., Sinha, S. C., Felding-Habermann, B., Smider, V. V. and Schultz, P. G. (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. P. Natl. Acad. Sci. U. S. A. 109, 16101-16106.
DOI
|